115 completed, 14 recruiting, 12 active not recruiting, 9 terminated. 61 Phase 3, 35 Phase 2, 22 Phase 1, 11 Phase 4, 5 Not applicable.
Follow Hereditary Complement Deficiency Diseases: new trials by email Literature Review of Hereditary Complement Deficiency Diseases trials Research Report on Hereditary Complement Deficiency Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study About the Diagnosis and Management of Hereditary Angioedema (HAE) in Egypt No intervention - Hereditary Angioedema (HAE) | Not yet recruiting | Takeda | 100 | 2026-12-01 | 2026-06-18 | |
| A Study of Takhzyro in Teenagers and Adults With Hereditary Angioedema (HAE) in South Korea No intervention - Hereditary Angioedema (HAE) | Recruiting | Takeda | 35 | 2026-09-21 | 2026-10-15 | |
| Safety and Effectiveness of Sebetralstat (KVD900) for Short-Term Prophylaxis Before Procedures in People With Hereditary Angioedema (KONTROL) KVD900 600 mg - Hereditary Angioedema | Phase 4 | Recruiting | KalVista Pharmaceuticals, Ltd. | 100 | 2026-08-17 | 2026-09-17 |
| A Study to Learn About the C1-Inhibitor Function as Diagnosis for Hereditary Angioedema Technochrom C1-INH Kit - Hereditary Angioedema (HAE) | Not applicable | Recruiting | Takeda | 514 | 2026-05-12 | 2026-05-19 |
| A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) in the Kingdom of Saudi Arabia No intervention - Hereditary Angioedema (HAE) | Recruiting | Takeda | 50 | 2026-04-30 | 2026-05-11 | |
| Donidalorsen Treatment in Children With Hereditary Angioedema Donidalorsen - Hereditary Angioedema (HAE) | Phase 3 | Recruiting | Ionis Pharmaceuticals, Inc. | 20 | 2026-04-21 | 2026-09-02 |
| Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE) ADX-324 Dose Level 1, ADX-324 Dose Level 2 - Hereditary Angioedema (HAE), Hereditary Angioedema - Type 1 | Phase 3 | Recruiting | ADARx Pharmaceuticals, Inc. | 90 | 2026-04-02 | 2026-09-04 |
| Real-life Ecological Momentary Assessment of Lived Burden in Hereditary AngioEdema ecological momentary assessment - Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1 | Recruiting | Istituti Clinici Scientifici Maugeri SpA | 30 | 2026-02-23 | 2026-03-04 | |
| A Study of Lanadelumab in Children With Hereditary Angioedema (HAE) in Multiple Countries No intervention - Hereditary Angioedema (HAE) | Completed | Takeda | 37 | 2026-02-05 | 2026-07-14 | |
| Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency Deucrictibant, Placebo - Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH) | Phase 3 | Recruiting | Pharvaris Netherlands B.V. | 48 | 2025-10-16 | 2026-09-21 |
| A Long-Term Study of Navenibart in Participants With Hereditary Angioedema navenibart - Hereditary Angioedema (HAE) | Phase 3 | Enrolling by invitation | Astria Therapeutics, Inc. | 145 | 2025-10-01 | 2026-07-30 |
| Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE TRIAL) Berinert, Placebo for Berinert - Kidney Transplant | Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 180 | 2025-09-22 | 2026-02-27 |
| STOP-HAE: A Phase 3 Study of ADX-324 in HAE ADX-324, Placebo - Hereditary Angioedema, HAE | Phase 3 | Recruiting | ADARx Pharmaceuticals, Inc. | 90 | 2025-08-28 | 2026-09-10 |
| A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE) No intervention - Hereditary Angioedemas | Recruiting | CSL Behring | 200 | 2025-07-21 | 2026-06-03 | |
| Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab Garadacimab - Hereditary Angioedema | Phase 4 | Completed | CSL Behring | 18 | 2025-04-28 | 2026-07-23 |
| A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE Attacks Inapplicable - Hereditary Angioedema | Completed | KalVista Pharmaceuticals, Ltd. | 88 | 2025-04-21 | 2026-01-13 | |
| A Study of Navenibart in Participants With Hereditary Angioedema navenibart, Placebo - Hereditary Angioedema (HAE) | Phase 3 | Active not recruiting | Astria Therapeutics, Inc. | 157 | 2025-03-20 | 2026-06-30 |
| Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients Deucrictibant XR tablet, Placebo comparator to XR tablet, Deucrictibant 20 mg capsule - Hereditary Angioedema (HAE), Angioedema | Phase 1 / Phase 2 | Recruiting | Institute for Asthma and Allergy | 10 | 2025-03-10 | 2025-07-02 |
| Suicide Ideation in Hereditary Angioedema Hereditary Angioedema (HAE), Suicidal Ideation | Not yet recruiting | Ivan Cherrez Ojeda | 100 | 2025-03-01 | 2025-02-10 | |
| HAE Burden and Crisis Management Hereditary Angioedema (HAE) | Completed | University Hospital, Grenoble | 300 | 2025-03-01 | 2026-04-29 |
Showing 20 of 173. Sign in to see all of them.
Angioedemas, Hereditary (169) · Angioedema (26) · Genetic Diseases, Inborn (9) · Hereditary Angioedema Types I and II (9) · Rare Diseases (6) · Immune System Diseases (4) · Cardiovascular Diseases (3) · Hereditary Angioedema Type III (3) · Hypersensitivity (3) · Urticaria (3) · Vascular Diseases (3) · Acquired angioedema (2) · Common Variable Immunodeficiency (2) · Communicable Diseases (2)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (173) · Immunologic Deficiency Syndromes (172) · Primary Immunodeficiency Diseases (172) · Immune System Diseases (169) · Skin and Connective Tissue Diseases (169) · Hypersensitivity, Immediate (167) · Skin Diseases (167) · Skin Diseases, Vascular (167) · Cardiovascular Diseases (166) · Hypersensitivity (166) · Urticaria (166) · Vascular Diseases (166) · Genetic Diseases, Inborn (164) · Angioedema (143)
Complement C1 Inhibitor Protein (25) · berotralstat (12) · icatibant (12) · Sodium Chloride (10) · conestat alfa (10) · lanadelumab (10) · sebetralstat (9) · SERPING1 protein, human (8) · donidalorsen (6) · ecallantide (6) · IONIS-PKK-LRx (5) · avoralstat (5) · Cyclosporine (2) · RNA, Small Interfering (2) · Anti-Bacterial Agents (1)
Shire (39) · Takeda (19) · BioCryst Pharmaceuticals (17) · KalVista Pharmaceuticals, Ltd. (12) · CSL Behring (11) · Pharming Technologies B.V. (8) · Pharvaris Netherlands B.V. (8) · Ionis Pharmaceuticals, Inc. (6) · Astria Therapeutics, Inc. (5) · University Hospital, Grenoble (4) · ADARx Pharmaceuticals, Inc. (3) · CENTOGENE GmbH Rostock (3) · Intellia Therapeutics (3) · Istituti Clinici Scientifici Maugeri SpA (3) · AO GENERIUM (2)
United States (85) · Germany (60) · United Kingdom (52) · Canada (48) · Italy (44) · France (38) · Spain (37) · Poland (33) · Israel (32) · Hungary (31) · Netherlands (27) · Australia (26) · Austria (23) · Bulgaria (22) · Japan (22)
Anurag Relan, MD (4) · Lauge Farnaes, MD (3) · Peter Bauer, MD (3) · Joanne Collier, MBChB, FFPM, Dip Stats (OU) (2) · Oksana A. Markova, MD (2) · Adrian Gadano, MD (1) · Aleena Banerji, M.D. (1) · Anne Pagnier (1) · Bruce Zuraw, MD (1) · Bruno Giannetti, MD (1) · David Hoover, MD (1)
PMID 36326435, PMID 36408587, PMID 20818886, PMID 23312695, PMID 23878046, PMID 24712435, PMID 23548529, PMID 42159953, PMID 42268494, PMID 20818888, PMID 20920772, PMID 21130380, PMID 22765833, PMID 22856635, PMID 23484892, PMID 23548526, PMID 23987198, PMID 25198193, PMID 28284978, PMID 36153561, PMID 36774155, PMID 37028510, PMID 40171989, PMID 40380356, PMID 40769455, PMID 40886933, PMID 42318595, PMID 1538192, PMID 15577929, PMID 16375711, PMID 17073887, PMID 19767078, PMID 20674826, PMID 20818887, PMID 21195947, PMID 21884533, PMID 21988742, PMID 22123383, PMID 22192966, PMID 22856636, PMID 22909164, PMID 23167682, PMID 23535096, PMID 24111645, PMID 24266596, PMID 24438203, PMID 24749847, PMID 24980392, PMID 25295804, PMID 25426834
2018 (3), 2004 (2), 2015 (2), 2023 (2), 2008 (1), 2009 (1), 2019 (1), 2025 (1)